The IND is More Just an FDA Submission: It’s a Regulatory Positioning Strategy

For decades, FDA's Investigational New Drug (IND) application has been viewed primarily as a regulatory gateway. Submit the application, obtain FDA's approval to proceed, and begin clinical trials.

But that view is increasingly becoming outdated.

Today, the IND is not simply an administrative milestone in development. It is the first major opportunity to position a product strategically with FDA. It is FDA's first impression of a product and it shapes how regulators are likely to evaluate the program throughout the lifecycle of development.

Sponsors that treat the IND as a tactical filing risk missed opportunities, avoidable regulatory friction, and downstream development delays. Sponsors that approach the IND more strategically establish alignment with FDA early, clarify development expectations, and create a regulatory narrative that supports the program through approval.

In today's environment, the IND has become a regulatory positioning document as much as a mere regulatory submission.

Why the Role of the IND Is Evolving

Drug development programs are more complex than ever and the landscape of regulatory review of new drugs is evolving. Emerging modalities, accelerated approval pathways, and increasing regulatory scrutiny mean that early regulatory alignment is critical.

At the same time, FDA's expectations for development program justification and scientific rationale have expanded significantly.

As a result, the IND is no longer just about demonstrating that a product is reasonably safe to begin clinical investigations. It has become the foundation upon which the entire development strategy is built.

Sponsors must now use the IND to communicate:

• The scientific rationale for the program (including a "reason to believe" for the drug's risk/benefit profile)
• The clinical development strategy
• How nonclinical and CMC data support early clinical investigation
• How the product may ultimately meet unmet medical needs
• How the program aligns with FDA regulatory frameworks

The way these elements are framed can influence ongoing regulatory dialogue for years to come.

Setting the Tone for the Entire Development Program

We are always taught that first impression matters in all aspects of life. Regulatory interactions and submissions are no exception to that rule.

When FDA reviews an IND, reviewers are not simply evaluating safety for initial clinical studies. They are also forming an early perspective on the sponsor's scientific rigor, quality assurance, development planning, and regulatory maturity.

A well-constructed IND establishes: 

• Credibility with FDA reviewers
• Confidence in the sponsor's scientific approach
• Alignment on development assumptions
• Clear justification for study design and dose selection

Conversely, poorly structured submissions or unclear regulatory narratives often lead to requests for additional information, clinical holds, or protracted regulatory dialogue.

In many cases, the questions raised during IND review foreshadow the issues that will arise later during End-of-Phase 2 discussions, NDA submission, and labeling negotiations.

The IND therefore becomes the first chapter of the regulatory story sponsors must tell throughout their product's development.

Regulatory Strategy Begins Before the IND is Written

The most effective INDs are not written at the end of development planning. They are the result of deliberate regulatory strategy established months in advance.

Key strategic questions must be addressed early, including:

• What clinical development pathway is most likely to support approval? Commercialization?
• How should early clinical studies be designed to generate regulatory-relevant evidence?
• Are there opportunities to pursue expedited pathways such as Fast Track, Breakthrough Therapy, or Accelerated Approval?
• What regulatory risks must be addressed proactively in the IND?

These considerations should shape how data is presented, how studies are designed, and how regulatory arguments are constructed.

Without this strategic foundation, sponsors risk submitting an IND that satisfies minimum regulatory requirements but fails to position the program effectively.

The Importance of Cross-Functional Alignment

An IND is often perceived as a regulatory affairs deliverable; but in reality, it represents the culmination of cross-functional development planning.

Successful IND submissions require tight coordination across:

• Regulatory affairs
• Clinical development
• Nonclinical and toxicology teams
• CMC and manufacturing experts
• Biostatistics
• Quality and compliance teams

Misalignment across these disciplines often manifests in inconsistent messaging, unclear development logic, or gaps in regulatory justification.

In contrast, cross-functional alignment ensures that the IND submission presents a coherent scientific and regulatory narrative, linking nonclinical data, manufacturing readiness, and clinical study design into a unified strategy.

The Growing Importance of the Pre-IND Meeting

Given the strategic importance of the IND submission, the pre-IND meeting has become one of the most critical regulatory interactions in early development.

This meeting provides sponsors with an opportunity to test key elements of their development strategy before submitting the IND to FDA, including:

• Proposed clinical trial designs
• Dose selection strategy
• Nonclinical data requirements
• Manufacturing readiness
• Opportunities for expedited regulatory pathways

Sponsors that use the pre-IND meeting strategically can reduce uncertainty, clarify FDA expectations, and significantly strengthen their IND submission.

However, the value of the meeting depends heavily on preparation and readiness. Poorly framed questions or incomplete briefing packages often limit the usefulness of FDA feedback. Seeking a meeting too early, before there is sufficient data in place to frame the discussion, can also lead to sub-optimal meeting outcomes and FDA feedback that is of limited value.

The Cost of Treating the IND as a Procedural Step

Sponsors that approach the IND as a routine regulatory filing frequently encounter avoidable development challenges. Common consequences include:

• Clinical holds due to insufficient nonclinical or CMC justification
• Requests for additional studies that delay development timelines
• Regulatory disagreements regarding study design
• Misalignment on development endpoints or target populations

In many cases, these issues could have been mitigated through earlier regulatory planning and stronger positioning within the IND submission.

As regulatory expectations continue to evolve, the cost of reactive development strategies will only increase.

Strategic IND Development Supports Long-Term Success

Sponsors that treat the IND as a strategic milestone gain several advantages and are better positioned to:

• Align development strategy with FDA expectations early
• Anticipate regulatory concerns before they become barriers
• Design clinical programs with approval requirements in mind
• Build regulatory credibility and establish rapport with agency reviewers
• Maintain development momentum across phases

In this sense, the IND is not simply the beginning of clinical development. It is the foundation of regulatory success.

Building an IND That Positions Your Program for Success

Developing a strategically positioned IND requires more than compiling data into a regulatory format fit for submission. It requires:

• Early regulatory strategy development
• Cross-functional alignment across development teams
• Thoughtful framing of scientific rationale and early development data
• Strategic engagement with FDA through the Pre-IND process
• Careful anticipation of regulatory risk

Sponsors that invest in this preparation are far more likely to achieve efficient regulatory interactions and maintain development timelines.

Regulatory Strategy Starts with the First Submission

In today's regulatory environment, the IND should no longer be viewed as a procedural checkpoint on the path to clinical development. It is the moment when sponsors begin formally presenting their development vision to regulators.

Those who approach the IND strategically can establish a strong regulatory foundation that supports the program through clinical development and ultimately toward approval.

Position Your IND for Success

ProPharma's team of regulatory experts support sponsors at every stage of IND preparation, including:

• Pre-IND regulatory strategy and gap assessments
• Briefing package development and FDA engagement planning
• Cross-functional development alignment
• IND submission preparation and lifecycle management

ProPharma: The World's Leading Regulatory Consultancy

Interested in learning how we can help your team achieve successful FDA interactions? Contact us today and connect with our regulatory scientists to ensure your IND submission positions your program for long-term success.